WO2004085452A1 - 石灰化組織親和性化合物 - Google Patents
石灰化組織親和性化合物 Download PDFInfo
- Publication number
- WO2004085452A1 WO2004085452A1 PCT/JP2004/004019 JP2004004019W WO2004085452A1 WO 2004085452 A1 WO2004085452 A1 WO 2004085452A1 JP 2004004019 W JP2004004019 W JP 2004004019W WO 2004085452 A1 WO2004085452 A1 WO 2004085452A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- calcified
- compound
- acid
- compound according
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/02—Acyclic radicals, not substituted by cyclic structures
- C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Definitions
- the present invention relates to a compound exhibiting rapid urinary release that is highly compatible with calcified paper, and to its use as a diagnostic agent, a therapeutic agent, and the like. Background leakage
- Bone scintigraphy imaging agents reduce the time from drug administration to imaging and reduce urinary excretion in addition to bone affinity and blood tissue clearance to obtain high scintigram image quality. Is required to be fast.
- radioactively labeled phosphate compounds are used. The first tested were inorganic polyphosphates labeled with 99m-technetium.
- inorganic polyphosphates labeled with 99m-technetium have a problem in that they are hydrolyzed in ZK solution to become monophosphates and thus have low clearance from blood.
- Ya ⁇ and the like were calculated to be 99 m-Tc-199m-ethane-1-hydroxy-1-diphosphonate first tin (Tc), an organic diphosphonic acid labeled with technetium.
- Tc first tin
- technetium an organic diphosphonic acid labeled with technetium.
- an object of the present invention is to design the organic phosphonic acid so that it is difficult to form a complex compound, and to control the size of the liver, thereby exhibiting an excellent affinity for calcification.
- the purpose of the present invention is to combine a novel organic phosphonic acid withdrawal that exhibits the ability in urine, and its use as a diagnostic agent, Jin-U, etc.
- the present inventor has conducted various studies on calcified ⁇ -miscible compounds such as organic phosphonic acids to achieve the above ⁇ 3 ⁇ 4, and found that the following HIS formula (AC) a — MC— (LI) to (In the formula, MC is a job, AC is a calcified knitting leak, LI is a ligand that can bond to a metal atom, a is an integer of 1 or more, and b is an integer of 0 or 1 or more.)
- AC a — MC—
- LI is a ligand that can bond to a metal atom
- a is an integer of 1 or more
- b is an integer of 0 or 1 or more.
- MC is a mother nucleus and is selected from the group consisting of amino group, amide group, hydroxyl group, thiol group, thioether group, sulfonyl group, phosphonyl group, aldehyde group, carbonyl group, carboxy group, halogen and cyano group ⁇ Of a compound with multiple ⁇ groups
- a C is a calcified male.
- LI is a ligand capable of binding to a metal atom.
- a and b are 1 or more »:
- the ligand LI can bind to a metal atom, that is, it may form a complex with the metal atom or may not form a complex.
- the LI moiety plays a central role in the complexing ability, the AC moiety is unlikely to form a complex compound, and the clearance of blood and / or soft paper cranes is fast and excretion into urine is also possible. It is convenient because it is fast.
- Preferred compounds of the present invention have the formula (AC) a -MC— (LI) b
- Abominable Mc is a compound selected from the group consisting of m oligosaccharides, amino sugars, cyclodextrins and sugar dendrimers, and a and b are integers of 1 or more.
- AC is preferably a calcified paper ⁇ -sum ttS composed of polyasparagine, polyglutamine, and organic phosphonic acid, and is an organic phosphonic acid group. Is preferred.
- MC is a ⁇ S of a disulfide compound selected from the group consisting of oligosaccharides, aminooligosaccharides, cyclodextrins, and sugar dendrimers.
- the ligand LI which can be bonded to a metal atom, is bonded to a structure M different from that of the subject ⁇ W.
- a and b are integers of 1 or more.
- a plurality of ligands LI capable of binding to AC or a metal atom may be bonded to the calcified crane.
- MC is a functional group selected from the group consisting of amino groups, amide groups, hydroxyl groups, thiol groups, thioether groups, sulfonyl groups, phosphonyl groups, aldehyde groups, carboxyl groups, carboel groups, phenols, rogens and cyano groups. Is a compound that has a plurality of calcifications.
- a is one or more difficulties.
- a calcified compound represented by the formula: This compound has a fiber MC with a controlled size, shows a better affinity for calcified cranes in AC, and shows a higher urinary concealment in tC, which does not accumulate in calcified tissue. It is convenient.
- MC is a residue of a compound selected from the group consisting of monosaccharides, oligosaccharides, aminooligosaccharides, cyclodextrins, and dendrimers, and AC is polyaspartic acid. It is preferably a calcified ( ⁇ -compatible) group consisting of a group, a polyglutamic acid group and an organic phosphonic acid group, and more preferably an organic phosphonic acid group.
- Preferred embodiments of the compound of the present invention include fiber MC, calcified thread II ⁇ tt3 ⁇ 4AC and At least one of the ligands LI contains a metal atom or contains a nitrogen atom, carbon, a bell, sulfur or phosphorus isotopes. This embodiment is particularly preferable for use as a diagnostic agent.
- Japanese Patent Application Laid-Open No. H10-501012 mentions that 99m-technetium mono-, di- or polyphosphonate complex exudates differ depending on conditions such as autoclave heating and micro-propulsion heat. It has been disclosed. This is an attempt to improve the clearance due to the formation of the polymer by the radioactive Fe-phosphate compound ⁇ ⁇ *. However, in this method, the mixture of polyphosphonate that still uses the polymer Is inevitable.
- the compound represented by the formula (AC) a — MC— (LI) b of the present invention distributes the labeling loss due to the radiation 'I to the ligand LI, and the bisphosphonic acid forms $ 1 [1] is to improve the relevance to more advantageous bones by reducing the chance of involvement. It is clear that similar thoughts can be made in the calcification of bisphosphonic acid £ W »tltt3 ⁇ 4AC.
- the difference in the complex-forming ability between the ligand: LI and the calcifying compatibility group AC can be proved by using a compound of the present invention.
- HIE can be performed by the labeling method of DTPA or MAG3 and HMDP.
- the compound represented by the formula (AC) a — MC of the present invention is not only useful as a therapeutic agent because it has calcifying and leaking properties itself, but also has a role in the occupational MC and the ashing motility group Ac. At least one of them can be labeled by including the same stereochemistry of a metal atom or a halogen atom, carbon, m, nitrogen, sulfur or phosphorus, and is therefore useful as a diagnostic agent.
- diagnostic agents in diagnostic medicine is increasing rapidly. Therefore, in nuclear medicine diagnosis, a textile or substance labeled with radioactivity is administered into a living body, radiation emitted by the substance or substance is detected by a scinticamera, and the composition or substance of the composition or substance is detected. Minutes in vivo It is widely used to express cloth and behavior as images in a non-comprehensive manner, and is used to discover various stores and elucidate pathological conditions.
- the extinct matter or substance labeled with this radioactive 4 ⁇ is called a radioactive imaging agent, and those suitable for each purpose have been developed.
- the contrast of SII may be increased by administering a thread or substance containing a normal metal species that enhances the texture of the surrounding protons.
- the compound of the present invention has a calcifying and reversible action, so that it can be used for the treatment of bone disease, arteriosclerosis such as calcified vascular sites, and stone lfiL duct lesions such as chronic inflammatory diseases. Can also be used.
- the compound of the present invention selectively adheres to the entire calcification in vivo, and It is useful as a diagnostic or therapeutic agent for each of the above.
- the compound of the present invention can be subjected to appropriate radionuclide labeling to diagnose bone diseases such as bone metastasis, osteoporosis, Paget's disease, fracture, ectopic ossification, bone formation or osteolysis, and the like.
- ⁇ Useful as a shelf component for diagnosis of calcified vascular sites such as hardening.
- the compound of the Lord is administered intravenously to the body of mammals, including humans, and then the distribution of radioactivity in the body is measured. It is done by doing. The f-distribution is determined using a device known to " ⁇ (such as gamma force melamine).
- the compound of the present invention is used as an anticancer agent for bone cancer and its metastasis, prevention of metastasis of the cancer to bone, etc. as a therapeutic agent for inflammation I 'bone disease and pain such as rheumatoid arthritis, illness, etc. Purpose of Can be translated Further, the compound of the present invention can be used for diagnosis due to difficulties such as selection of efficacy and efficacy.
- the compound of the present invention can be used as an imaging or therapeutic agent in various types of image diagnosis using radiation, nuclear resonance, X-ray, ultrasound, or the like, depending on the type of the labeling substance contained therein. Further, the compound of the present invention or a salt thereof can be provided as a medicament together with at least one pharmaceutically acceptable compound.
- the occupation MC may be any one provided with a plurality of functional groups that can be chemically bonded to the calcified paper art 'and the ligand LI. Specifically, it is selected from the group consisting of an amino group, an amide group, a hydroxyl group, a thiol group, a thioether group, a sulfonyl group, a phosphonyl group, an aldehyde group, a carboxyl group, a carbonyl group, a halogen group and a 'cyano group. Examples of the compound having a plurality of groups include wisteria.
- a monosaccharide, an oligosaccharide, a polysaccharide, an amino acid, an oligopeptide, a polypeptide, a nucleotide, an oligonucleotide, a polynucleotide, a protein, a protein fragment, or a chemical fragment thereof can be used. It may be a book or a compound liver.
- the compound of the present invention can control the molecular size depending on the size of the mother nucleus MC, it can control the blood vessel and the interwoven fabric by controlling the size of the liver depending on the intended use. 1 1 ⁇ ⁇ is effectively ffied and ⁇ ! Acts selectively. ”
- the fiber MC is a saccharide compound selected from the group consisting of saccharides, oligosaccharides, aminooligosaccharides, cyclodextrins and dendrimers, and more preferably oligosaccharides, aminooligosaccharides, cyclodextrin sucrose. It is a residue of a dendrimer, particularly preferably a wisteria of oligosaccharide and amino-oligosaccharide. Examples include glucose, mannose, galactose, dalcosamine, mannosamine, galactosamine and the like.
- Oligosaccharides include those composed of at least one member selected from the group consisting of glucose, mannose, galactose and the like. These may be linear or carried, and are preferably a polymer of 2 to 20 saccharides from the viewpoint of the compatibility between the blood vessel and the fiber of the compound of the present invention. Also, the oligosaccharide may be one in which the structure ⁇ H is mutually bonded or / 3 bonded, or one in which the structure is 1-3, 1-4 or 1-16 bonded to each other. There may be.
- oligosaccharides include maltotriose, maltotetraose, maltopenose, maltohexaose, maltoheptaose, isomaletotriose, isomalttetraose, isomaltopenose, isomalthexaose, Isomaltheptaose, cellotriose, serotetraoose, ceropeneose, seguchihexaose, laminaritriose, laminaritetraose, laminaripenaeose, laminarihexaose, laminarihebeose, elrose, panose , Rafinose and the like. Oligosaccharides may or may not be present in the final part, such as " ⁇ ", but those which are preferred are preferred. ⁇ Oligosaccharides also include these dialdehyde saccharides .
- amino oligosaccharide examples include those having 1 WJi amino sugar selected from the group consisting of dalcosamine, mannosamine, galactosamine, and the like. These may be fibers, and from the viewpoint of the novelness of the compound of the present invention between blood vessels, it is preferably a polymer of 2 to 20 sugars, and 2 to 13 sugars are preferred. Polymers of the following are more preferred.
- the amino oligosaccharide may be one in which the components ⁇ ! Are mutually ⁇ - or) 3 linked, or one in which the components are 1-3, 1-4 or 1-6 bonded to each other. May be.
- amino-oligosaccharides include chitosan oligosaccharides having a repeating unit of 2 to 10 and galactosamine oligosaccharides having a repeating unit of 2 to 10 such as a chitosan disaccharide.
- Chitosan trisaccharide Chitosan tetrasaccharide
- Examples include chitosan oligosaccharides such as chitosan pentasaccharide and chitosan hexasaccharide, and galactosamine oligosaccharides such as galactosamine disaccharide, galactosamine trisaccharide, galactosamine tetrasaccharide, galactosamine pentasaccharide, and galactosamine hexasaccharide.
- the amino oligosaccharide may or may not be reduced in ⁇ such as: ⁇ , but preferably is reduced.
- the amino oligosaccharides also include those in which the amino group is N-acetylated, and also include dialdehyde saccharides.
- Cyclodextrins include hi-, / 3- and arcyclodextrins. Also, cyclodextrins Also included are dihydrated sugars with ji3 ⁇ 4 at the third position.
- sugar dendrimer examples include those in which fiber or a branched sugar is bonded to a core made of a polycarboxylic acid or an alkyl polycarboxylic acid.
- the sugar dendrimer is expressed by generation and has a structure in which a circle can be drawn from the inner core to the outside.
- the number of circles of polycarboxylic acid is preferably 1 to 5 generations, more preferably 1 to 3.
- sugar dendrimers include those in which a linear or branched sugar is attached to a core made of polyamine or alkylpolyamine.
- the sugar dendrimer takes a nitrogen atom that forms a circle from the inner nucleus to the nitrogen atom, and a sugar is bonded to the:! ⁇ To form a sugar dendrimer.
- the number of circles is preferably from 1 to 5 generations, more preferably from 1 to 3.
- fiber MC having a phosphonyl group includes inositol-3-phosphate
- mother nucleus MC having a sulfonyl group includes chondroitin sulfate, heparan sulfate, and keratan sulfate.
- the fiber C having a lipoxyl group or a carbonyl group is, for example, glucuronic acid.
- the fiber having a halogen of 1 to 1 is MC, acetobromo-1-D-dalcuronic acid methyl ester (Acetobromo-a- D-glucuronic acid methyl ester).
- Examples of the fiber MC having a cyano group include cyanomethyl mannose.
- Calcification »Measuring group AC is not limited as long as it is a compound that is #f sensitive to calcifications found in blood vessels, etc.
- polyaspartic acid poly Examples include glutamic acid, organic phosphonic acids and their derivatives.
- Examples of the organic phosphonic acid constituting the calcifying finely divided group AC include diphosphonic acid represented by the following formula I and derivatives thereof, and wisteria of these salts.
- R 1 and R 3 may be the same or different
- R 17 are each independently ⁇ or ⁇ 03 ⁇ 4 € 3 ⁇ 4
- R 7 , R 10 and R 13 are each independently sulfur, oxygen, amide, imide, a divalent heterocyclic ring composed of 3 to 12 atoms and a hydrocarbon (Ar R r 19 ) s ) is a group selected from the group consisting of:
- R 18 is "CR 17 ;
- organic phosphonic acid represented by the above formula I examples include, for example, ethylene glycol-1,2-bisphosphonic acid, diphosphonomethanesulfonic acid, 2,2-diphosphonoethanesulfonic acid, 2,2-diphosphono-2-acid
- examples thereof include hydroxyethanesulfonic acid, 1,1-diphosphono-2-hydroxyethanesulfonic acid, N, N-dimethyl-1-aminoethane-1,1,1-diphosphonic acid, and derivatives thereof.
- the substituents R 1 and R 2 on the alpha carbon may be hydrogen, 7 acid groups, amino groups, halogen groups, carboxylic acid groups, sulfone ms, lower alkyl groups, alkyl alcohol groups, cyano groups, etc., and R 1 and R 2 Either binds to the nucleus of the parent MC.
- R 1 is of the formula CR 14 !? 15 ⁇ where R 14 and k 15 3 ⁇ 4H
- Such bisphosphonic acids include, for example, methanediphosphonic acid (MDP), hydroxymethanediphosphonic acid (HMDP), 1-hydroxyethane-1,1-bisphosphonic acid (E HDP), dimethylaminomethylene diphosphonic acid (DMAD), 3, 3- Jihosuhono - 1, 2-propane diphosphonate (DPD), Re ChikaraYasushi galley such chilled port sulfonate (Tildronate)
- MDP methanediphosphonic acid
- HMDP hydroxymethanediphosphonic acid
- E HDP 1-hydroxyethane-1,1-bisphosphonic acid
- DMAD dimethylaminomethylene diphosphonic acid
- DPD 2-propane diphosphonate
- Re ChikaraYasushi galley such chilled port sulfonate
- Tildronate such chilled port sulfonate
- MDP HMDP EH0P DMAD DPD Tildronate methanediphosphonic acid (MDP), etc. can be obtained by the method described in (for example, J. Org.ChenL, 66 (11),
- the organic phosphonic acid of the present invention can be obtained by inducing as shown below.
- Alendronate which is a hydroxybisphosphonic acid
- Alendronate which is a hydroxybisphosphonic acid
- Methods for chemically bonding the organic phosphonic acid to the fiber MC include, for example, amidation, esterification, imidation, and the like.
- organic phosphonic acid an organic aminophosphonic acid derivative in which a group represented by the formula II is bonded to an amine »atom, or an estere or salt thereof can be used.
- X and Y are each hydrogen, halogen, hydroxy, carbonyl, carboxy, phosphonic, and C 1 to C 8 carbon atoms.
- R 2 o is selected from hydrogen, silyl, alkyl, benzyl, sodium and potassium.
- organic phosphonic acid examples include a phosphonic acid derivative represented by the formula III, and esters or salts thereof.
- A, B, C, D, E and F are each hydrogen, methyl, ethyl, isopropyl, bivaloyl, benzyl, acetyl, trifluoroacetyl, and the following formula IV.
- A, B, C, D, E and F is a group of the following formula IV-1)
- pV-3] (t, X and Y are the same as in Formula II. is 2 or 3, and X 'and Y' are each independently selected from hydrogen, methyl and ethyl, and X 'and Y', respectively. May be the same or different.)
- phosphonic acid derivative represented by the formula III examples include ethylenediaminetetramethylenephosphonic acid (EDTMP) and ethylenetriamineamine.
- organic phosphonic acids include decorative phosphoric acid typified by EDTMP and DTPMP. These compounds, like bisphosphonic acid, have bone It is said to be a translator.
- Polyaspartic acid having a degree of polymerization of 4 to 12 can be preferably used. Further, as polyglutamic acid, those having a polymerization degree of 4 to 12 can be preferably used.
- Examples of the method for chemically bonding the above-mentioned organic phosphonic acid, polyaspartic acid or boridalutamic acid to the mother nucleus MC include amidation, esterification and imidation.
- examples of the ligand (LI) capable of binding to a metal atom include those capable of forming a complex with a metal atom or metal ion.
- the ligand (LI) as used herein means a compound capable of forming a complex with a metal atom or metal ion.
- the ligand (LI) is typically a ligand or a polydentate ligand, that is, a ligand containing two or more coordinating atoms per ligand.
- a coordinating atom is defined as an atom that forms an electron pair that can bond to a metal atom. this Is preferably composed of two or more coordinating atoms.
- the coordinating atom is selected from nitrogen, sulfur, phosphorus and carbon, and is z or oxygen and z or sulfur.
- boridedentate or polydentate ligand examples include a linear or cyclic polyaminopolycarboxylic acid or a fibrous or cyclic polyaminopolyphosphonic acid, or a primer thereof.
- polyaminopolycarboxylic acid examples include ethylenediamine diacetate, nitric triacetic acid, ethylenediaminetetraacetic acid (hereinafter abbreviated as EDTA), diaminocyclohexanetetraacetic acid, diethylenetriaminepentaacetic acid (DTPA), 1,4-, 7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA), 1,4,8,11-tetraazacyclotetradecane 1,4,8,11 monotetraacetic acid (TETA) or derivatives thereof.
- polyaminopolyphosphonic acid include EDTMP or a derivative thereof.
- polyaminopolycarboxylic acid inducers include, for example, esterification, halogenation or protection of one or more hydroxyl groups of polyaminopolycarboxylic acid to a hydrocarbon group having a substituent or a substituent of carboxylic acid.
- Substituted compounds also compounds in which a hydrocarbon group comprising a polyaminopolycarboxylic acid is substituted with a carboxylic acid substituent, and a carbon-based substituent or a carbon-containing reductive group is introduced.
- Compounds in which an ether group or the like has been introduced into the carbon skeleton of minopolycarboxylic acid can be mentioned.
- hydroxyethyl ethylenediaminetriacetic acid diaminopropanoltetraacetic acid, N, N-bis (2-hydroxybenzyl) ethylenediaminediacetic acid, and glycol etherdiaminetetraacetic acid.
- ligands as ligands (LI), cyclam (cyc 1 am), N ⁇ 1-2,3-dioleic propyl) propyl ⁇ -N, N, N, triethylammonium (DOTMA), Mercaptoacetyldaricylglycylglycine (MAG3), ethylene cis Tin dimer (ECD), hydrazino nicocelle (HYNI C), lysine-tyrosine-cysteine (KYC), cysteine-glycine-cystine (CYC), N, N, monobis (mercaptoacetamide) ethylenediamine (DADS), N , N, - bis (Melka Butase evening bromide) -2, 3 Jiaminpuropan acid (C_ ⁇ 2 DADS) ( ⁇ FCW first ⁇ 173 424 JP and U.S.
- DOTMA triethylammonium
- MAG3 Mercaptoacetyl
- ligands include 6-hydrazinonicotinic acid or a group of polydentate having sulfur and nitrogen as coordinating atoms such as diaminodithiol, monoaminomonoamidodithiol, diamidodithiol, and triamidothiol.
- Ligand can also be used for complex formation.
- N N'-bis (2-mercaptoethyl) ethylenediamine, 2,2,9,9-tetramethylylate 4,7-diaza-1,10-decanethiol
- N- (2-mercaptoethyl) aminoethyl-12-mercaptoacetamide 1,2-ethylenebis (2-mercaptodiamide as diamidedithiol Acetamide) and triamidothiol are specifically exemplified by chelating groups such as mercaptoacetyl daricyldaricyldaricin.
- polydentate ligands include macrocyclic and open-chain 4, 5, 6, 7, and 8 compounds with or without other coordination atoms or unsaturated bonds.
- the binding between these ligands (LI) and the fiber MC can be achieved by chemically bonding the functional group of the ligand, which is not necessary for complexing the metal, with the functional group of the fiber MC.
- the ligand (LI) may be a bifunctional ligand.
- the bifunctional ligand is It is a compound having both a bond with the MC and a complex formation site with the metal. Therefore, the number of bifunctional ligands corresponding to the number of fg groups can be converted to physiologically acceptable substances through the government available for binding to the bifunctional ligands in the MC. Can be combined.
- the complex formation with the metal is not limited as long as it is a polydentate ligand that forms a complex with each metal, but it is usually a cyclic or fibrous polyaminopolycarboxylic acid. It can be selected from acids or cyclic or linear polyaminopolyphosphonic acids, for example, EDTA, DTPA, DOTA, TETA or their elicitation or EDTMP or its elicitation, or MAG3, cyclam, BAT, ECD, DADS and PnAO or their invitations are used.
- the reactive linking group in the bifunctional ligand that forms the bond with MC includes ordinary amino group, carbonyl group, thiol group, active octogen, alkoxyester, N-hydroxysuccinimide Specific examples thereof include esters, imide esters, maleimides, thiophthalimides, isothiocyanates, and acid anhydrides.
- bifunctional ligand examples include, for example, 1- (p-isothiosinate benzyl) -DTPA [Martin WB et al., Inorg. Chem., 25, 2772-2781 (1986 )], Anhydrous DTPA, 2- (p-isothiocyanatobenzyl) -1,4,7,10-tetraazacic dodecane-1,4,7,10-tetraacetic acid [US Pat. No. 4,678,667] Succinimidyl-1-hydrazinonicotinate [Abrams, MJ et al., J. Nuc 1.
- the bond between MC and the bifunctional ligand may be performed by the method of ⁇ 0 itself.
- the reactive linking group of the bifunctional ligand is an acid anhydride [Hnowowich DJ et al., Int. J. App 1. Rad. Isot., 33, pp. 327-332 ( 1982)], isothiocyanate [Est eban JM et al., J. Nuc 1. Med., 28, 861
- Preferred ligands are ethylenediaminetetraacetic acid (EDTA), diethylenetriaminepentaacetic acid (DTPA), triethylenetetramine hexaacetic acid ( ⁇ ), cyclam (eye 1 am), 1,4,8,11-tetra Azacyclotetradecane-1,4,8,11-tetraacetic acid (TETA), 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA), N ⁇ 1 — 2,3-dioleic xy) propyl ⁇ 1 N, N, N, 1 triethylammonium (DOTMA), mercaptoacetyldaricyl glycine (MAG 3), ethylene cysteine dimer (ECD), hydrazino nicotine (HYNIC), U-gin-tyrosine-cysten (KYC), cysteine-glycine-cystine (CYC), N, N, -bis (mer
- Complexation of the metal atom with the ligand (LI) is performed by a conventional method.
- Complexing metal Atoms can be selected according to the intended use, and usually a dead atom useful as a target substance is selected.
- Such metal atoms include radioactive, paramagnetic I or X-ray opaque metal atoms or their ions.
- the compound of the present invention may contain a metal atom or a halogen atom, a carbon atom, an oxygen atom, a crane, or the like, regardless of the presence or absence of the ligand LI. It may contain sulfur or phosphorus isotopes.
- a metal atom or a halogen atom a carbon atom, an oxygen atom, a crane, or the like, regardless of the presence or absence of the ligand LI. It may contain sulfur or phosphorus isotopes.
- the halogen atom fluorine, sulfur, iodine and the like are preferably used.
- the introduction of these halogen atoms can be performed by introducing the substituent into which the detoxification of Toshiru Fuji has been introduced into Fiber MC or calcified fiber '! AC, and then substituting the halogen atom with this substituent.
- the halogen atom is substituted with this substituent.
- a substituent such as a metal alkyl group such as trialkyltin represented by the formula Sn (R 3 ) into the fiber MC or the calcifying edible group AC
- the halogen atom is substituted with this substituent. You can also do this.
- the alkyl group of the metal alkyl group a methyl group, an ethyl group, a propyl group, a butyl group and the like are used.
- Preferred metal alkyl groups are trimethyltin or 1, liptyltin.
- ligand (LI) can be introduced by reacting a carboxylic acid of a polycarboxylic acid (such as DTPA) constituting the above-mentioned ligand (LI) with methylamine (u CHgNHs) (-CONH ⁇ CHg). Further, it can also be introduced by using a positive glucose derivative (Japanese Unexamined Patent Application Publication No. 09-176179, Japanese Unexamined Patent Application Publication No. 09-176550, Japanese Unexamined Patent Application Publication No. 2 6 7 9 8
- the metal atom or the isotope of metal contained in the complex of ⁇ 3 ⁇ 4s, or the metal atom or the isotope ⁇ contained in the fiber MC, calcification ia » ⁇ 43 ⁇ 4AC or the ligand LI is selected according to the application.
- radiodiagnostics include gamma-emitting, normal organs or tissue Those that do not significantly damage the weave are selected.
- the emission ffl bell preferably has an imageable gamma ray or can be mixed with a radionuclide containing an imageable gamma ray (doping).
- This dope pink can be the same or different if its chemistry is sufficiently close to the beta-emitting nuclide and its biodistribution in the use of the invention is close to or the same as that of the beta emitter. Good.
- Radiotherapy applications are selected that release base particles and cure the diseased area, but do not significantly damage normal organs or tissues in the fiber.
- These cumshots 25-2. Has an average ⁇ energy of 75 MeV, may or may not have gamma rays that can be imaged, and the average softset is 0.70 to 25.0 mm, with a half of 0.05 to 700 hours. Good to do.
- Preferred metal atoms and isotopes include atomic numbers 6 to 9, 15 to 17, 21 to 29, 31, 35, 37 to 44, 49, 50, 53, 56 to 70, 72 to 75, 81 , 83 and 85 are selected from the group consisting of the elements.
- preferred metal atoms and the same stereochemistry include 11-C, 15-0, 18-F, 32-P, 59-Fe, 67-Cu, 67-Ga, 81-Rb, 89-Sr , 90—Y, 99m—Tc, 111—In, 123—1, 124—1, 125—1, 131-1, 117m—Sn, 153—Sm, 186—Re, 188—Re, 201—Tl, Radioactivity selected from the group consisting of 211—At, 212—B i and 213-B i, and among these, preferably 32—P, 59—Fe, 67—Cu, 67—Ga, 81—Rb, 89-S r, 90—Y, 99m—Tc, 111—In, 123—1, 124—1, 125—1, 131—1, 117m—Sn, 153—Sm, 186_Re, 188—Re, 201—T Radioactive difficulties selected from the group consisting of
- preferred metal atoms and isotopes are chromium (III), manganese (II), iron (II), iron (III), Praseodymium (III), Neodymium (III), Samarium (III), Itterpiu (III), gadolinium (III), terbium (III), dysprosium (III), holmium (III) and erbium (III).
- preferred metal atoms and isotopes are bismuth, tungsten, tantalum, lanthanide, humidium, lanthanum, lanthanide, norium, molybdenum, and niobium. , Zirconium and strontium.
- the calcified yarn !! Senwa 'I43 ⁇ 4A C and ligand LI may be linked to the worker AC via a linker L.
- bivalent reagent examples include N-succinimidyl-3- (2-pyridyldithio) propionate (SPDP), ethylene glycol mono-O, 0, monobis (succinimidyl succinate) (EGS), and N- (4-maleimidobutylic acid) Xy) succinimide (GMBS), N- (4-maleimidobutylene xy) sulfosuccinimide sodium salt (Su 1 f o-GMBS), N— (6-maleimidocaproyloxy) sulfo succinimide sodium salt (Su 1 f o-EMCS), N— (8-maleimidocapryloxy) sulfosuccinimide sodium salt (Su 1 f o-HMCS), N— (11—maleimidoundecanolyloxy) sulfosuccinimide sodium salt (Su 1 f o-KMUS), 3,3,1-dithiopis (sulf
- the reaction between linker L and the fiber MC and the reaction between linker L and the above-mentioned component AC and ligand LI can be performed by the method of ⁇ ⁇ itself, for example, 1 ⁇ 0 or?
- the reaction of linking DTPA-mono (2-aminoethylamide) or DTPA-mono (6-aminohexylamide) to the amino group of the ab fragment via EGS or DT SSP is described in Patent No. 2815156.
- Patent No. 2 548 711 when polylysine is used Patent No. 17 291 192 when polyacrolein is used, and dialdehyde starch as MC
- a diamino oligosaccharide it can be carried out according to Patent No. 17214409, Japanese Patent Application Laid-Open No. 7-206895, and the like.
- R and R are AC or a ligand LI capable of binding to a metal atom, and at least one is a calcifying chemistry group AC.
- X and y Respectively, 0 to 19 in lBsi.
- X + y is 1 to 19.
- the compound shown above is an aminoamino group composed of at least one selected from the group consisting of dalcosamine, mannosamine and galactosamine, which constitutes the MC.
- Bisphosphonate dagger (BP) as AC It can be easily obtained by reacting and reacting the carboxylic acid group of polyaminopolycarboxylic acid as ligand LI.
- the amino-oligosaccharide may or may not be present.
- the terminal end is reduced, the final amino group of the amino oligosaccharide is modified with a protecting group so that the desired compound is added to the terminal amino group of the reducing oligosaccharide. This is convenient because it can be chemically bonded.
- the diamino oligosaccharide is preferably 2 to 50 sugars, more preferably 2 to 20 sugars, and particularly preferably 2 to 13 sugars.
- a method for selectively repairing the final amino group can be provided by performing a reaction for the formation of a sulfamate compound.
- a final amino acid composed of at least one selected from the group consisting of darcosamine, mannosamine and galactosamine: M Is reacted with dibutyl dicarbonate, and the final amino group is selectively repaired with a butoxyl group (Boc) group.
- the compounds of the present invention may be in the form of salts, salts, solvates.
- Salts include pharmaceutically acceptable salts with alkaline metals such as lithium, sodium and potassium, salts with inorganic groups such as salts with alkaline earth metals such as calcium and magnesium, and ammonium salts.
- alkaline metals such as lithium, sodium and potassium
- salts with inorganic groups such as salts with alkaline earth metals such as calcium and magnesium
- ammonium salts ethylamine, dimethylamine, getylamine, trimethylamine, triethylamine, cyclohexylamine, ethanolamine, diethanolamine, salts with organic groups such as morpholine and meglumine, and basic amino acids such as lysine, orditin and arginine are exemplified.
- sodium and potassium are used with care.
- the compound of the present invention can be used in the form of a solid body, a water upset, or a carved form.
- a radioactive labeling / reversion kit preparation What is the radiolabeled parenteral kit containing the compound of the present invention? It is preferably used as a male dry agent. It is dissolved when used and is labeled with a radionuclide such as technetium or rhenium metal salt for administration.
- a radioactive transition metal such as technetium or rhenium metal salt in the presence of a nonmetallic reducing agent by using a transmutation method or a conventional method for transmutation, and then used for administration.
- Compounds of the present invention may be in the form of S ⁇ MC or calcified sum
- Convenient forms are groups, de-US, or substituted with substituents, including metal alkyl groups. Fluorine, iodine, and the like are preferably used for the halogen group, and trialkyltin represented by the formula Sn (R 3 ) is used for the metal alkyl group. A methyl group, an ethyl group, a propyl group, and a butyl group are used for the alkyl group. Are used. Preferably, trimethyltin or triptyltin is used.
- Radiation ttA-logenization of the substituent X is carried out by the following method, preferably by substitution or 3-fold reaction.
- the kit for preparing a radioactive compound may include a conventionally used plowing agent such as an oxidizing agent, a ⁇ mmmm excipient, or the like.
- a conventionally used plowing agent such as an oxidizing agent, a ⁇ mmmm excipient, or the like.
- chloramine ⁇ or ii-oxygen is added as an oxidizing agent, if necessary, to be used for the reaction.
- the dimensions of this method are as follows. ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇
- the complex with the compound of the present invention can be transferred. It can be labeled by growing metal.
- the reaction conditions such as boat and pH, are not particularly limited. The reaction force under the key temperature or heating is 1 depending on the reaction conditions of these reactions.
- the compounds of the present invention may be physiologically acceptable relaxed IJ (eg, physiological diets, acetic acid, phosphoric acid, carbonic acid, ⁇ of tris (hydroxymethyl) aminomethane and the like! I) and other physiologically acceptable compounds. It may contain a stimulant (for example, a stabilizer such as ascorbic acid or parabens, or an excipient such as D-mannitol such as medalmin or benzoin).
- a stimulant for example, a stabilizer such as ascorbic acid or parabens, or an excipient such as D-mannitol such as medalmin or benzoin.
- the compounds of the present invention may be used as diagnostic agents or therapeutic agents! It can be used in the same manner as I. For example, it is used after being administered by ft to mammals, including t.
- the dosage is substantially the same as that of conventional diagnostic or therapeutic agents.
- the diagnostic agent is about 3 to 25 MBd / kg, preferably about 6 to 12 M3 ⁇ 4 / kg, or the cure depends on the weight of the patient used. .
- the dose may be appropriately adjusted depending on the type of the compound, the type of the drug, the patient's age, body weight, symptoms, administration method, concomitant use with other drugs, and the like. Difficult case
- WSCD 1-Ethyl-1-3- (3-getylaminopropyl) carbodiimide
- HO Bt ⁇ H 20 1-Hydroxytriazole-7 f
- DTPA Diethylenetriaminepentaacetic acid
- HP LC High Performance Liauid Chromatography
- — ⁇ Ac acetyl group
- B oc- tert-butoxycarbonyl group
- B n- benzyl group.
- "Satsu operation" in the description was performed under the following conditions.
- ⁇ Transparent gland MICROACILYZER G 3 Drops Product name, Asahi Ka fiber type shelf
- Dialysis membrane AC-110-400 Drop name, Asahi Fiber type
- Vt1 The synthesis scheme of Vt1 is shown below.
- Oxyphosphoryl) propanoic acid (3.45 g, 5.80 mol), dissolved in methylene chloride (50 mL), and placed in an ice bath.
- 929 mg (5.80 thigh ol) of WS CD and 789 mg (5.84i dish ol) of HOB t ⁇ ⁇ 2 ⁇ were added, followed by ⁇ H (about 19.5 hrs).
- the solvent of the reaction mixture was distilled off, 43 mL of pyridin was added to the residue, the mixture was cooled in a water bath, 11.3 mL (11.98 mmol) of acetic anhydride was added, and the mixture was stirred for 17 hours. In an ice bath, 21 mL of methanol was added and continued for another 15 minutes.
- the solvent of the reaction mixture was distilled off, extraction was performed (cloth form: 150 mL / water: 100 mL ⁇ 2), the organic layer was sickled with anhydrous sodium sulfate, and the solvent was distilled off.
- the residue was dissolved in 20 mL of dimethylformamide by exciting Q, and the solvent was distilled off to obtain a residue (about 7. g).
- the residue was dissolved in 10 mL of methanol, 5 mL of a 10% hydrochloric acid-methanol solution (manufactured by Tokyo Chemical Industry Co., Ltd.) was added, and the mixture was heated at room temperature for 3 hours.
- the solvent of the reaction solution was distilled off to obtain 481 mg of a residue.
- 4.43 mL of water and 1.63 mL of an 8 mol / L aqueous sodium hydroxide solution were added to the residue and the reaction was won. Heated to 80, 1. Ug of anhydrous DTPA (3.11 ol) was added and the win continued for 30 minutes.
- the mixture was returned to room temperature, adjusted to pH 9 by adding an aqueous solution of 8 ⁇ sodium oxide, and heated again at 80 for 30 minutes.
- E - pan r 500MHz, D 2 0, TSP: 2. 62 (IE 3 ⁇ 4 - C3 ⁇ 4CH-), 2. 83 (23 ⁇ 4 ra, - C0C3 ⁇ 4CH -), 3. 52- 3. 97 (54H, IE), 4.33 (IS m), 4.72 (2H, m).
- Synthetic product VI-1 was mixed with stannous chloride water falcon night. Physiological ⁇ 7JC containing 17-20 mCi of pertechnetate was added to the mixture, and left at room temperature to perform the reaction.
- Example 3
- Urine (% ID) 44. 674 ⁇ 2.565 As shown above, urine preparation was performed promptly and blood clearance was also rapid. The calcified mouth also showed high accumulation. Also, in marked contrast to the commercially available composition DP injection described for comparison, in the above example the optimization was carried out in view of the fact that no purification or optimization was performed on the genuine product of the present invention. It will be apparent that the compositions of the present invention exhibit even more dramatic advantages.
- Example 4 (Fiber-like Boc y JiS with chitotritor
- Chitotritol was selectively induced into Boc according to the following reaction formula, and induced.
- triol hydrochloride (3.06 g, 5.00 l) were dissolved in 20 mL of methanol and 40 mL of water, and 2.23 g (21.1 l ol) of sodium carbonate and 1.3 lg of dibutyl dicarbonate (6. 00 t). The reaction mixture was won at room temperature for 22 hours, and the solvent was removed. The obtained ⁇ was dissolved in 50 mL of methanol, 1.63 g (12. Ommol) of P-anisaldehyde was added, and the mixture was stirred at room temperature for 24 hours. Next, the religion was rejected, and the obtained evacuation system was purified with hexane and then dried overnight at room temperature.
- a compound in which a calcified crane fineness-compatible group AC is bound to a mother nucleus MC having a controlled size This compound shows an excellent arrowhead property of the calcified body, and shows a compound power that did not bellow the calcified body, and its secretion in urine.
- ligand LI is bound to MC, and label leakage due to complex formation and the like is shared with ligand LI, making it difficult for the affinity group AC to form a complex compound. Clearance of urine and ⁇ tt into urine can be done further J ⁇ !
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Molecular Biology (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Crystallography & Structural Chemistry (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Optics & Photonics (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005504075A JP4723378B2 (ja) | 2003-03-26 | 2004-03-24 | 石灰化組織親和性化合物 |
AU2004223955A AU2004223955A1 (en) | 2003-03-26 | 2004-03-24 | Compound having affinity with calcified tissue |
US10/550,724 US20060189567A1 (en) | 2003-03-26 | 2004-03-24 | Compound having affinity with calcified tissue |
EP04722978A EP1609797A1 (en) | 2003-03-26 | 2004-03-24 | Compound having affinity with calcified tissue |
BRPI0408717-8A BRPI0408717A (pt) | 2003-03-26 | 2004-03-24 | composto tendo afinidade com tecido calcificado |
CA002520147A CA2520147A1 (en) | 2003-03-26 | 2004-03-24 | Compound having affinity with calcified tissue |
NO20054914A NO20054914L (no) | 2003-03-26 | 2005-10-24 | Forbindelse med affinitet til kalsifisert vev |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003-085919 | 2003-03-26 | ||
JP2003085919 | 2003-03-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004085452A1 true WO2004085452A1 (ja) | 2004-10-07 |
Family
ID=33095045
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/004019 WO2004085452A1 (ja) | 2003-03-26 | 2004-03-24 | 石灰化組織親和性化合物 |
Country Status (11)
Country | Link |
---|---|
US (1) | US20060189567A1 (ja) |
EP (1) | EP1609797A1 (ja) |
JP (1) | JP4723378B2 (ja) |
KR (1) | KR20050109608A (ja) |
CN (1) | CN1764670A (ja) |
AU (1) | AU2004223955A1 (ja) |
BR (1) | BRPI0408717A (ja) |
CA (1) | CA2520147A1 (ja) |
NO (1) | NO20054914L (ja) |
TW (1) | TW200505934A (ja) |
WO (1) | WO2004085452A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008266194A (ja) * | 2007-04-19 | 2008-11-06 | Hiroshi Tanaka | 分子プローブの原料として有用な新規有機化合物 |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9820986B2 (en) * | 2005-03-04 | 2017-11-21 | Taiwan Hopaz Chems, Mfg. Co., Ltd. | Glycopeptide compositions |
CN107326674A (zh) * | 2017-07-21 | 2017-11-07 | 安徽华锦柏亚纤纺科技有限公司 | 一种涤棉梭织物的防水防油整理方法 |
CN108872131A (zh) * | 2018-08-16 | 2018-11-23 | 浙江诚意药业股份有限公司 | 一种鉴别甲壳类氨基葡萄糖和微生物法氨基葡萄糖的方法 |
JP2022547638A (ja) * | 2019-09-03 | 2022-11-14 | プロサイプラ セラピューティクス, エルエルシー | 新規の多形およびその使用 |
KR20210031159A (ko) * | 2019-09-11 | 2021-03-19 | 주식회사 엘지화학 | 리튬 이차전지용 비수전해액 및 이를 포함하는 리튬 이차전지 |
CN114652852A (zh) * | 2020-12-22 | 2022-06-24 | 浙江大学 | 诱导肿瘤细胞发生自发钙化的分子及其应用 |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5750928A (en) * | 1980-09-13 | 1982-03-25 | Nippon Mejifuijitsukusu Kk | Diagnostic agent for scanning bone |
JPS59205331A (ja) * | 1983-04-18 | 1984-11-20 | アメルシヤム・インタ−ナシヨナル・パブリツク・リミテツド・コムパニ− | テクネチウム−99mの骨探査錯体 |
WO1989011877A2 (en) * | 1988-06-10 | 1989-12-14 | Neorx Corporation | Conjugates for bone imaging and bone cancer therapy |
JPH0285239A (ja) * | 1988-06-07 | 1990-03-26 | Nippon Mejifuijitsukusu Kk | ジエチレントリアミン五酢酸誘導体とその用途 |
JPH04202197A (ja) * | 1990-11-30 | 1992-07-22 | Ihara Chem Ind Co Ltd | 還元ヘキサ―n―アセチル―キトヘキサオースを有効成分とする抗腫瘍剤 |
JPH07206895A (ja) * | 1993-10-22 | 1995-08-08 | Nippon Mejifuijitsukusu Kk | 炎症親和性ペプチド及び該ペプチドを含有してなる放射性診断剤 |
JP2001114792A (ja) * | 1999-10-12 | 2001-04-24 | Nihon Medi Physics Co Ltd | ビスホスホン酸誘導体およびその放射性核種標識体 |
JP2002187948A (ja) * | 2000-10-11 | 2002-07-05 | Sumitomo Chem Co Ltd | アミド化合物の製造方法 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5094950A (en) * | 1988-06-07 | 1992-03-10 | Nihon Medi-Physics Co., Ltd. | Diethylenetriamine pentaacetic acid derivatives |
US5250702A (en) * | 1988-06-07 | 1993-10-05 | Nihon Medi-Physics Co., Ltd. | Diethylenetriamine pentaacetic acid derivatives |
US5202109A (en) * | 1988-06-10 | 1993-04-13 | Neorx Corporation | Conjugates for bone imaging and bone cancer therapy |
ATE175976T1 (de) * | 1993-10-22 | 1999-02-15 | Nihon Mediphysics Co Ltd | Peptide mit affinität für entzündungen und deren radiomarkierte, diagnostische zusammensetzungen |
IL145723A0 (en) * | 2000-10-11 | 2002-07-25 | Nihon Mediphysics Co Ltd | Process for producing an amide compound |
-
2004
- 2004-03-23 TW TW093107856A patent/TW200505934A/zh unknown
- 2004-03-24 WO PCT/JP2004/004019 patent/WO2004085452A1/ja active Application Filing
- 2004-03-24 CN CNA2004800081662A patent/CN1764670A/zh active Pending
- 2004-03-24 EP EP04722978A patent/EP1609797A1/en not_active Withdrawn
- 2004-03-24 JP JP2005504075A patent/JP4723378B2/ja not_active Expired - Fee Related
- 2004-03-24 US US10/550,724 patent/US20060189567A1/en not_active Abandoned
- 2004-03-24 AU AU2004223955A patent/AU2004223955A1/en not_active Abandoned
- 2004-03-24 BR BRPI0408717-8A patent/BRPI0408717A/pt not_active Application Discontinuation
- 2004-03-24 CA CA002520147A patent/CA2520147A1/en not_active Abandoned
- 2004-03-24 KR KR1020057018116A patent/KR20050109608A/ko not_active Application Discontinuation
-
2005
- 2005-10-24 NO NO20054914A patent/NO20054914L/no unknown
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5750928A (en) * | 1980-09-13 | 1982-03-25 | Nippon Mejifuijitsukusu Kk | Diagnostic agent for scanning bone |
JPS59205331A (ja) * | 1983-04-18 | 1984-11-20 | アメルシヤム・インタ−ナシヨナル・パブリツク・リミテツド・コムパニ− | テクネチウム−99mの骨探査錯体 |
JPH0285239A (ja) * | 1988-06-07 | 1990-03-26 | Nippon Mejifuijitsukusu Kk | ジエチレントリアミン五酢酸誘導体とその用途 |
WO1989011877A2 (en) * | 1988-06-10 | 1989-12-14 | Neorx Corporation | Conjugates for bone imaging and bone cancer therapy |
JPH04202197A (ja) * | 1990-11-30 | 1992-07-22 | Ihara Chem Ind Co Ltd | 還元ヘキサ―n―アセチル―キトヘキサオースを有効成分とする抗腫瘍剤 |
JPH07206895A (ja) * | 1993-10-22 | 1995-08-08 | Nippon Mejifuijitsukusu Kk | 炎症親和性ペプチド及び該ペプチドを含有してなる放射性診断剤 |
JP2001114792A (ja) * | 1999-10-12 | 2001-04-24 | Nihon Medi Physics Co Ltd | ビスホスホン酸誘導体およびその放射性核種標識体 |
JP2002187948A (ja) * | 2000-10-11 | 2002-07-05 | Sumitomo Chem Co Ltd | アミド化合物の製造方法 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008266194A (ja) * | 2007-04-19 | 2008-11-06 | Hiroshi Tanaka | 分子プローブの原料として有用な新規有機化合物 |
Also Published As
Publication number | Publication date |
---|---|
JP4723378B2 (ja) | 2011-07-13 |
KR20050109608A (ko) | 2005-11-21 |
TW200505934A (en) | 2005-02-16 |
US20060189567A1 (en) | 2006-08-24 |
CN1764670A (zh) | 2006-04-26 |
BRPI0408717A (pt) | 2006-03-07 |
AU2004223955A1 (en) | 2004-10-07 |
NO20054914L (no) | 2005-11-03 |
CA2520147A1 (en) | 2004-10-07 |
JPWO2004085452A1 (ja) | 2006-06-29 |
EP1609797A1 (en) | 2005-12-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7059372B2 (ja) | デュアルモードの放射性トレーサーおよび療法剤 | |
RU2742660C9 (ru) | Конъюгированные бисфосфонаты для диагностики и терапии заболеваний костей | |
BR112021015035A2 (pt) | Agentes de imagem para diagnóstico de câncer | |
JP5167285B2 (ja) | 診断および放射線治療用の造影剤とその調製方法 | |
JP7145156B2 (ja) | 二量体造影剤 | |
Meckel et al. | A DOTA based bisphosphonate with an albumin binding moiety for delayed body clearance for bone targeting | |
Urbanovský et al. | Lanthanide complexes of DO3A–(dibenzylamino) methylphosphinate: effect of protonation of the dibenzylamino group on the water-exchange rate and the binding of human serum albumin | |
WO2004085452A1 (ja) | 石灰化組織親和性化合物 | |
CN116981486A (zh) | 双模式放射性示踪剂和治疗剂 | |
JP2001114792A (ja) | ビスホスホン酸誘導体およびその放射性核種標識体 | |
IE904319A1 (en) | 10-(2'-Hydroxy-3'POLYOXAALKYL)-1,4,7-TRISCARBOXYMETHYL-¹1,4,7,10-TETRAAZACYCLODODECANE | |
Liu et al. | An osteoclast-targeting agent for imaging and therapy of bone metastasis | |
CA2394959A1 (en) | Labelled ascorbic acid derivatives | |
AU2021252191B2 (en) | Pharmaceutical formulations |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005504075 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004722978 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 170867 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2520147 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004223955 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006189567 Country of ref document: US Ref document number: 1020057018116 Country of ref document: KR Ref document number: 20048081662 Country of ref document: CN Ref document number: 10550724 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 542762 Country of ref document: NZ |
|
ENP | Entry into the national phase |
Ref document number: 2004223955 Country of ref document: AU Date of ref document: 20040324 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2004223955 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 1020057018116 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2004722978 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: PI0408717 Country of ref document: BR |
|
WWP | Wipo information: published in national office |
Ref document number: 10550724 Country of ref document: US |